Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer

Akihiro Kogita, Yosuke Togashi, Hidetoshi Hayashi, Eri Banno, Masato Terashima, Marco A. De Velasco, Kazuko Sakai, Yoshihiko Fujita, Shuta Tomida, Yoshifumi Takeyama, Kiyotaka Okuno, Kazuhiko Nakagawa, Kazuto Nishio

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Non-small cell lung cancer (NSCLC) carrying echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) rearrangements is hypersensitive to ALK inhibitors, including crizotinib and alectinib. Crizotinib was initially designed as a MET inhibitor, whereas alectinib is a selective ALK inhibitor. The MET signal, which is inhibited by crizotinib but not by alectinib, is dysregulated in many human cancers. However, the role of the MET signal in ALK-positive NSCLC remains unclear. In this study, we found that hepatocyte growth factor (HGF), ligand of MET, mediated the resistance to alectinib, but not to crizotinib, via the MET signal in ALK-positive NSCLC cell lines (H3122 and H2228 cell lines). In addition, alectinib activated the MET signal even in the absence of HGF and the inhibition of the MET signal enhanced the efficacy of alectinib. These findings suggest that activated MET acts as a salvage signal in ALK-positive NSCLC. This novel role of the MET signal in ALK-positive NSCLC may pave the way for further clinical trials examining MET inhibitors.

Original languageEnglish
Pages (from-to)1025-1030
Number of pages6
JournalInternational Journal of Oncology
Volume46
Issue number3
DOIs
Publication statusPublished - Mar 1 2015
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Hepatocyte Growth Factor
Cell Line
anaplastic lymphoma kinase
CH5424802
Clinical Trials
Ligands
crizotinib
Neoplasms

Keywords

  • Alectinib
  • Crizotinib
  • EML4-ALK rearrangement
  • MET
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer. / Kogita, Akihiro; Togashi, Yosuke; Hayashi, Hidetoshi; Banno, Eri; Terashima, Masato; De Velasco, Marco A.; Sakai, Kazuko; Fujita, Yoshihiko; Tomida, Shuta; Takeyama, Yoshifumi; Okuno, Kiyotaka; Nakagawa, Kazuhiko; Nishio, Kazuto.

In: International Journal of Oncology, Vol. 46, No. 3, 01.03.2015, p. 1025-1030.

Research output: Contribution to journalArticle

Kogita, A, Togashi, Y, Hayashi, H, Banno, E, Terashima, M, De Velasco, MA, Sakai, K, Fujita, Y, Tomida, S, Takeyama, Y, Okuno, K, Nakagawa, K & Nishio, K 2015, 'Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer', International Journal of Oncology, vol. 46, no. 3, pp. 1025-1030. https://doi.org/10.3892/ijo.2014.2797
Kogita, Akihiro ; Togashi, Yosuke ; Hayashi, Hidetoshi ; Banno, Eri ; Terashima, Masato ; De Velasco, Marco A. ; Sakai, Kazuko ; Fujita, Yoshihiko ; Tomida, Shuta ; Takeyama, Yoshifumi ; Okuno, Kiyotaka ; Nakagawa, Kazuhiko ; Nishio, Kazuto. / Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer. In: International Journal of Oncology. 2015 ; Vol. 46, No. 3. pp. 1025-1030.
@article{155b4662d8cf4fdfaf5e76256470ff6c,
title = "Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer",
abstract = "Non-small cell lung cancer (NSCLC) carrying echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) rearrangements is hypersensitive to ALK inhibitors, including crizotinib and alectinib. Crizotinib was initially designed as a MET inhibitor, whereas alectinib is a selective ALK inhibitor. The MET signal, which is inhibited by crizotinib but not by alectinib, is dysregulated in many human cancers. However, the role of the MET signal in ALK-positive NSCLC remains unclear. In this study, we found that hepatocyte growth factor (HGF), ligand of MET, mediated the resistance to alectinib, but not to crizotinib, via the MET signal in ALK-positive NSCLC cell lines (H3122 and H2228 cell lines). In addition, alectinib activated the MET signal even in the absence of HGF and the inhibition of the MET signal enhanced the efficacy of alectinib. These findings suggest that activated MET acts as a salvage signal in ALK-positive NSCLC. This novel role of the MET signal in ALK-positive NSCLC may pave the way for further clinical trials examining MET inhibitors.",
keywords = "Alectinib, Crizotinib, EML4-ALK rearrangement, MET, Non-small cell lung cancer",
author = "Akihiro Kogita and Yosuke Togashi and Hidetoshi Hayashi and Eri Banno and Masato Terashima and {De Velasco}, {Marco A.} and Kazuko Sakai and Yoshihiko Fujita and Shuta Tomida and Yoshifumi Takeyama and Kiyotaka Okuno and Kazuhiko Nakagawa and Kazuto Nishio",
year = "2015",
month = "3",
day = "1",
doi = "10.3892/ijo.2014.2797",
language = "English",
volume = "46",
pages = "1025--1030",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer

AU - Kogita, Akihiro

AU - Togashi, Yosuke

AU - Hayashi, Hidetoshi

AU - Banno, Eri

AU - Terashima, Masato

AU - De Velasco, Marco A.

AU - Sakai, Kazuko

AU - Fujita, Yoshihiko

AU - Tomida, Shuta

AU - Takeyama, Yoshifumi

AU - Okuno, Kiyotaka

AU - Nakagawa, Kazuhiko

AU - Nishio, Kazuto

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Non-small cell lung cancer (NSCLC) carrying echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) rearrangements is hypersensitive to ALK inhibitors, including crizotinib and alectinib. Crizotinib was initially designed as a MET inhibitor, whereas alectinib is a selective ALK inhibitor. The MET signal, which is inhibited by crizotinib but not by alectinib, is dysregulated in many human cancers. However, the role of the MET signal in ALK-positive NSCLC remains unclear. In this study, we found that hepatocyte growth factor (HGF), ligand of MET, mediated the resistance to alectinib, but not to crizotinib, via the MET signal in ALK-positive NSCLC cell lines (H3122 and H2228 cell lines). In addition, alectinib activated the MET signal even in the absence of HGF and the inhibition of the MET signal enhanced the efficacy of alectinib. These findings suggest that activated MET acts as a salvage signal in ALK-positive NSCLC. This novel role of the MET signal in ALK-positive NSCLC may pave the way for further clinical trials examining MET inhibitors.

AB - Non-small cell lung cancer (NSCLC) carrying echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) rearrangements is hypersensitive to ALK inhibitors, including crizotinib and alectinib. Crizotinib was initially designed as a MET inhibitor, whereas alectinib is a selective ALK inhibitor. The MET signal, which is inhibited by crizotinib but not by alectinib, is dysregulated in many human cancers. However, the role of the MET signal in ALK-positive NSCLC remains unclear. In this study, we found that hepatocyte growth factor (HGF), ligand of MET, mediated the resistance to alectinib, but not to crizotinib, via the MET signal in ALK-positive NSCLC cell lines (H3122 and H2228 cell lines). In addition, alectinib activated the MET signal even in the absence of HGF and the inhibition of the MET signal enhanced the efficacy of alectinib. These findings suggest that activated MET acts as a salvage signal in ALK-positive NSCLC. This novel role of the MET signal in ALK-positive NSCLC may pave the way for further clinical trials examining MET inhibitors.

KW - Alectinib

KW - Crizotinib

KW - EML4-ALK rearrangement

KW - MET

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84921934141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921934141&partnerID=8YFLogxK

U2 - 10.3892/ijo.2014.2797

DO - 10.3892/ijo.2014.2797

M3 - Article

C2 - 25502629

AN - SCOPUS:84921934141

VL - 46

SP - 1025

EP - 1030

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 3

ER -